Once reconstituted, store refrigerated
Use only in accordance with applicable research guidelines.
4145 Studies have shown that GLP-1 and its receptor agonists not only inhibit the levels of total cells, neutrophils, macrophages, eosinophils, lymphocytes, TNF-, IL-4, IL-5 and IL-13 in mouse alveolar lavage fluid 46 but also mediate anti-inflammatory effects through stress-activated protein kinase (JNK) inhibition, signal transducer and activator of transcriptional activator protein 3 (STAT3) activation and cAMP/PKA/NF-B signaling pathways, reducing the release of pro-inflammatory markers (iNOS, IL-1, IL-6, TNF- and monocyte chemotactic protein-1 (MCP-1), MMP-2, MMP-9, ROS) and increasing the release of anti-inflammatory markers (IL-10, mannose receptor-1 (MRC-1), arginine-1 (Arg-1) release as well as prostaglandin E2 (PGE2) and cyclooxygenase 2 (COX2) mRNA and COX2 protein levels, 42,46 thereby achieving a reduced inflammatory response

Most GLP-1a weight loss and type diabetes medications require a prior authorization (PA) from the insurance provider: FDA-approved weight loss medications: Contrave, Saxenda (liraglutide), Wegovy (semaglutide) Zepbound (tirzepatide) FDA-approved Diabetes medications: Rybelsis, Victoza (liraglutide), Ozempic (semaglutide), or Mounjaro (tirzepatide) If your insurance company says that they cover FDA-approved diabetes medications, it suggests coverage for patients with type 2 diabetes
Week 1: Early Pharmacodynamic Changes What the trials documented: The Phase 1b combination study measured reduced food intake and slowed gastric emptying among the earliest pharmacodynamic signals after dosing began, while the dose was still at the lowest titration step (Enebo et al., 2021)